Halozyme Therapeutics/$HALO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Halozyme Therapeutics

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Ticker

$HALO
Sector
Primary listing

Employees

350

HALO Metrics

BasicAdvanced
$8.9B
17.43
$4.37
1.17
-

What the Analysts think about HALO

Analyst ratings (Buy, Hold, Sell) for Halozyme Therapeutics stock.

Bulls say / Bears say

Total Q2 revenue climbed 41% year-over-year to $326 million, with royalty revenue surging 65% to $206 million, demonstrating robust adoption of the high-margin ENHANZE platform (Reuters).
Management raised full-year 2025 guidance a second time, projecting revenue of $1.275 billion to $1.355 billion and adjusted EBITDA of $865 million to $915 million, underscoring confidence in sustained growth (Reuters).
Net income increased 77% to $165 million in Q2, reflecting strong operating leverage and efficiency gains from expanding royalties and collaboration revenues (Reuters).
CMS draft guidance under the IRA could subject ENHANZE-based combination products to price negotiations just 13 years after original drug approval rather than combination approval, threatening royalty protections and future revenue streams (Reuters).
Halozyme’s key ENHANZE patents expire in 2027, raising long-term sustainability concerns as biosimilar competition and non-injectable delivery innovations could erode its royalty base once exclusivity lapses (Seeking Alpha).
Halozyme faces ongoing patent litigation after filing suit against Merck over its subcutaneous Keytruda formulation, exposing the company to costly legal battles and uncertain royalty outcomes if patents are invalidated (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

HALO Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

HALO Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HALO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs